Brolucizumab Switch and Extend Ph IIIb Study: A Canadian, multi-center, single-arm, open label study assessing the efficacy and safety of brolucizumab 6mg in a Treat and Extend regimen in patients with nAMD with prior anti-VEGF exposure (PEREGRINE)